Clinical Evidence

Delve into clinical research studies and more

Clinical research lies at the heart of who we are. Vantive uses scientific evidence systematically, and transparently, to inform the development of new state-of-the-art solutions for patients around the world. Here you can find various studies, white papers and articles concerning important topics across the wide range of therapy areas served by Vantive.

HDx therapy enabled by the Theranova Dialyzer
Medium cut‑off dialyzer improves erythropoiesis stimulating agent resistance in a hepcidin‑independent manner in maintenance hemodialysis patients: results from a randomized controlled trial
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Medium-cut off hemodialysis with theranova dialyzer as an alternative to hemodiafiltration: A prospective cohort study
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Membrane Innovation in Dialysis - Boschetti-de-Fierro A et al.
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Membrane innovation: closer to native kidneys - Storr M, Ward RA.
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Middle cut off (MCO) dialyzers in patients with multiple myeloma - removal of light chains with HDx-therapy
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Middle molecule elimination in expanded haemodialysis: only convective transport?
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Middle molecules removal and anticoagulation in hemodialysis with a medium cut off membrane: preliminary data from a monocentric trial
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Middle-Molecule Uremic Toxins and Outcomes in Chronic Kidney Disease
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Modeling of Internal Filtration in Theranova Hemodialyzers
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Most recently developed polyester polymer alloy dialyzer: A new medium cut-off membrane?.
Visit resource site
HD
Multicenter, prospective, randomised, crossover trial to demonstrate the benefits of hemodialysis without acetate (with citrate): ABC-treat study - Sequera et al.
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Multidimensional Classification of Dialysis Membranes
Visit resource site

Important Safety Information

INTENDED USE

The Theranova Dialyzer is indicated for patients with chronic kidney failure who are prescribed intermittent hemodialysis. It provides an expanded solute removal profile with increased removal of various middle molecules (up to 45 kDa) that may play a pathologic role in the uremic clinical syndrome. The Theranova Dialyzer is not intended for hemofiltration or hemodiafiltration therapy. The total extracorporeal blood volume for the Theranova Dialyzer and the set should represent less than 10% of the patient's blood volume.

For single use only.

 

Rx Only. For safe and proper use of the products mentioned herein, please refer to the appropriate Operator’s Manual or Instructions for Use.

 

Vantive, HDx and Theranova are trademarks of Vantive Health LLC or its affiliates.